Pharmacotherapeutic monitoring of nivolumab use in patientes with lung cancer
DOI:
https://doi.org/10.55892/jrg.v7i14.1046Keywords:
Lung cancer, Nivolumab, Pharmacotherapeutic monitoringAbstract
Cancer is a pathology that can develop in the body through the abnormal and disordered growth of cells. Lung cancer is among the most feared types of cancer, affecting both men and women. The use of nivolumab in antineoplastic therapy is of great importance, as this drug is effective against several neoplasms, including kidney and lung neoplasms, melanoma, among others. This is because nivolumab works by reducing T cell anergy in relation to neoplastic antigens. However, this drug has certain side effects, which may result in poor adherence to treatment. This is an integrative literature review (RIL). 16 articles were found that met the inclusion and exclusion criteria. It is concluded that the participation of the pharmacist interacting with the multidisciplinary team in the oncology sector is of paramount importance. Since this health professional contributes numerous advantages to patients, whether in the selection of drugs, analysis of prescriptions, pharmacotherapeutic monitoring and adherence to pharmacological treatment, in drug interactions, improving the relationship between patient and pharmacist. In this way, minimizing prescription errors and monitoring the lung cancer patient during her treatment, avoiding the appearance of adverse effects and therapeutic failures.
Downloads
References
AGUIAR, K. S.; SANTOS, J. M.; CAMBRUSSI, M. C.; PICOLOTTO, S.; CARNEIRO, M. B.; Segurança do paciente e o valor da intervenção farmacêutica em um hospital oncológico. einstein (São Paulo): 16(1), 2018.
ANG, Y. LE; LIM, J. S.; SOO, R. A. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets and Therapy, [s.l.], v. 9, p. 3187–3195, 2016. DOI: 10.2147/OTT.S84356.
ARAUJO, L H.;BALDOTTO, C.; CASTRO, Jr. G. de; KATZA., FERREIRA, C. G.; MATHIAS, C.; MASCARENHAS, E.; LOPES, G. de L.; CARVALHO, H.; TABACOF, J.; MARTÍNEZ-MESA, J.; VIANA, L. de S.; CRUZ, M. de S.; ZUKINn, M.; MARCHI, P. D.; TERRA, R. M.; RIBEIRO, R. A.; LIMA V. C. C. de.; WERUTSKY, G. Lung cancer in Brazil. Jornal Brasileiro de Pneumologia, 44(1), 55–64, 2018.
BOTELHO, L.L.R.; CUNHA, C. C. A.; MACEDO, M. O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade, v. 5, n. 11, p. 121-136, 2011.
CONSELHO FEDERAL DE FARMÁCIA. Programa de Suporte ao Cuidado Farmacêutico na Atenção à Saúde. Monitorização Terapêutica de Medicamentos. 2020, p 88.
DE SOUZA, M.C; VASCONCELOS, A.G; REBELO, M.S; REBELO, P.A; CRUZ O.G. Profile of patients with lung cancer assisted at the National Cancer Institute, according to their smoking status, from 2000 to 2007. Rev Bras Epidemiol. 17(1):175-88, 2014.
DRUGS.COM. List of Anti-PD-1 monoclonal antibodies (Anti-programme cell death protein 1 monoclonal antibodies) - Drugs.com. c2000-2010. 2018. Acesso em 04.03.2024.
EMA. Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products (EMEA/CHMP/BWP/157653/2007). Guideline, [s.l.], v. 44, no July, p. 1–13, 2016.
EUROPEAN MEDICINES AGENCY, E. Assessment report. In: Committee for Medicinal Products for Human Use (CHMP). [s.l.]: [s.n.], 2015. Acesso em 05.04.24.
HOCHHEGGER, B.; ALVES, G.R.T.; IRION, K.L.; FRITCHER, C.C.; FRITSCHER, L.G.; CONCATTO, N.H. PET/CT imaging in lung cancer: indications and findings. J bras pneumol. May;41(3):264–74, 2015.
IARC. Agência Internacional de Pesquisa sobre o Câncer. Observatório Global do Câncer. Lyon: IARC; c2018-2019. Disponível em: https://gco.iarc.fr/ Acesso em: 01.11.23
INCA. Instituto Nacional do câncer. 2023a. Câncer de pulmão. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/pulmao Acesso em: 01.11.23.
INCA. O que é câncer. 2023b. Disponível em: https://www.inca.gov.br/o-que-e-cancer. Acesso em: 17.11.23.
JIN, C.; ZHANG, X.; ZHAO, K.; XU, J.; ZHAO, M.; XU, X. The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. Onco Targets Ther. Mar 16;9:1571-8, 2016.
KAZANDJIAN, D.; SUZMAN, D.L.; BLUMENTHAL, G.; MUSHTI, S.; HE, K.; LIBEG, M.; KEEGAN, P.; PAZDUR, R.; FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist. may;21(5):634-42, 2016.
MASHIMA, E.; INOUE, A.; SAKURAGI, Y.; YAMAUCHI, T.; SASAKI, N.; HARA, Y.; OMOTO, D.; OHMORI, S.; HARUYAMA, S.; SAWADA, Y.; YOSHIOKA, M.; NISHIO, D.; NAKAMURA, M. Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther. Aug 6;8:2045-51, 2015.
SANTOS, A.F.; JAMES, L.K.; BAHNSON, H.T.; SHAMJI, M.H.; COUTO-FRANCISCO, N.C.; ISLAM, S.; HOUGHTON, S.; CLARK, A.T.; STEPHENS, A.; TURCANAU, V.; DURHAM, S.R.; GOULD, H.J.; LACK, G. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. may;135(5):1249-56, 2015.
SILVA, M.J.S.; OSORIO-DE-CASTRO, C.G.S. Organização e práticas da assistência farmacêutica em oncologia no âmbito do Sistema Único de Saúde. Interface (Botucatu, Online); 23: e180297, 2019.
THERAPEUTIC GOODS ADMINISTRATION, T. Australian Public Assessment Report for nivolumab. Camberra: [s.n.], 2016. Acesso em 05.04.2024.
WEBER, J.S.; D'ANGELO, S.P.; MINOR, D.; HODI, F.S.; GUTZMER, R.; NEYNS, B.; HOELLER, C. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16 (4), 375-384, 2015.
WHO, W. H. O. WHO Global Conference on Noncommunicable diseases: Enhancing policy coherence between different spheres of policy making that have a bearing on attaining SDG target 3.4 on NCDs by 2030. WHO. World Health Organization, 2019. Acesso em: 23.02.24
WORLD HEALTH ORGANIZATION, W. Cancer. WHO. World Health Organization, 2017. Disponível em ISSN: WHO/HTM/GMP/2016.6, DOI: /entity/mediacentre/factsheets/fs297/en/index.html. Acesso em 01.04.24.
